Background Analysis: US FDA Advisory Committee to Review Acadia’s Nuplazid (Pimavanserin) for Parkinson’s Disease Psychosis – MAR 29, 2016 (PDAC)
The US FDA has scheduled a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for Tuesday, March 29, 2016. The Committee will discuss the risk-benefit profile for a new drug application (NDA) for Nuplazid (pimavanserin), submitted by Acadia Pharmaceuticals Inc. (Acadia) for the proposed treatment of psychosis associated with Parkinson's disease.
See the SAC Tracker report